Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054578 | 0.87 | ERBB2 (0.36) | CYP3A4 | |
| SCHEMBL26727604 | 0.81 | POLB (0.38) | ALDH1A1CYP3A4HTR2ASMN1; SMN2POLB | |
| SCHEMBL25844870 | 0.78 | MAOB (0.34) | ALDH1A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL16042631 | 0.77 | RAB9A (0.36) | ALDH1A1CYP3A4SMN1; SMN2POLBMEN1 | |
| SCHEMBL25844890 | 0.77 | MAOB (0.34) | ALDH1A1CYP3A4 | |
| SCHEMBL1465286 | 0.73 | CYP3A4 (0.39) | ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL3163857 | 0.73 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL25844894 | 0.73 | XDH (0.42) | ALDH1A1CYP3A4HTR2ASMN1; SMN2GSK3B | |
| SCHEMBL4490974 | 0.72 | KMT2A (0.35) | ALDH1A1CYP3A4POLBMEN1KMT2A | |
| SCHEMBL7773643 | 0.72 | ALDH1A1 (0.60) | ALDH1A1CYP3A4SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4212528-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | GPR55, GPR65, GPR4 | ALDH1A1 1764/4885CYP3A4 287/4885HTR2A 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.